Creative Planning
VYNT

Creative Planning’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Creative Planning’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-27
Closed -$5K – 4975
2016
Q4 		$5K Buy
+27
New +$6.14K ﹤0.01% 3990

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Creative Planning's VYNT Position: Q1 2017 in Review

Creative Planning sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2017, closing a stake of 27 shares — an estimated $5K sold.

Creative Planning first reported a position in VYNT in Q4 2016 and held it in 1 quarter. The position peaked at $5K in Q4 2016. 32 funds tracked by Wall St. Rank hold VYNT as of Q1 2017.

  • Creative Planning reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Creative Planning sold 27 Vyant Bio, Inc. Common Stock shares in Q1 2017, an estimated $5K.
  • Creative Planning first reported a position in Vyant Bio, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Creative Planning's Vyant Bio, Inc. Common Stock position peaked at $5K in Q4 2016.
  • 32 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2017.

Based on Creative Planning's 13F filing for Q1 2017, filed 7 Apr 2017.